<DOC>
	<DOCNO>NCT01764997</DOCNO>
	<brief_summary>Primary Objective : To demonstrate treatment effect sarilumab methotrexate ( MTX ) compare etanercept methotrexate ( MTX ) patient rheumatoid arthritis ( RA ) inadequate response adalimumab methotrexate evaluation Disease Activity Score 28 joint ( DAS28 ) . Secondary Objectives : To assess sign symptom rheumatoid arthritis ( RA ) patient take sarilumab combination methotrexate ( MTX ) . To assess quality life patient rheumatoid arthritis ( RA ) take sarilumab combination methotrexate ( MTX ) . To assess safety tolerability sarilumab combination methotrexate ( MTX ) patient rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>An Evaluation Sarilumab Plus Methotrexate Compared Etanercept Plus Methotrexate RA Patients Not Responding Adalimumab Plus Methotrexate</brief_title>
	<detailed_description>The maximum study duration per patient enrol Main study 54 week broken follow : - screening/run-in maximum 24 week - treatment maximum 24 week - follow-up 6 week treatment discontinuation . The maximum study duration per patient enrol Sub-study 58 week broken follow : - treatment maximum 52 week - follow-up 6 week treatment discontinuation .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion criterion : Diagnosis rheumatoid arthritis ( RA ) &gt; /= 3 month duration . Continuous treatment methotrexate ( MTX ) 10 25 mg/week ( per local labeling requirement dose range differs ) least 12 week screen visit stable dose 8 week screen visit . Active disease define : least 6/66 swollen 8/68 tender joint high sensitivity Creactive protein &gt; 10 mg/L . Exclusion criterion : Age &lt; 18 year . Use parenteral corticosteroid intraarticular corticosteroid within 4 week screen visit . Use oral corticosteroid dose high prednisone 10 mg equivalent per day , change dosage within 4 week screen visit . Prior treatment TNF ( tumor necrosis factor ) alpha inhibitor , biological disease modify antirheumatoid drug ( DMARD ) Janus Kinase inhibitor . New treatment doseadjustment ongoing nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 inhibitor ( COX2 inhibitor within 4 week screen visit . Treatment traditional oral diseasemodifying antirheumatic drug ( DMARD ) /immunosuppressive agent MTX within 4 week 12 week screen visit , depend DMARD . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>